SUB: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for re-appointment of the Mr. Rishav Mehta as Executive Director;
Dear Sir,
Pursuant to the provisions of Regulation 30 and any other applicable provisions, if any, of the Securities and Exchange of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (hereinafter "SEBI Listing Regulations") please note that the Board of Directors in their meeting held on today i.e. 10th August, 2022, have considered and approved the reappointment of and payment of remuneration to Mr. Rishav Mehta (DIN: 00015407), Executive Director of the company for a period of next five years w.e.f. 23rd March, 2023 as recommended by Nomination and Remuneration Committee, Subject to the approval of the Shareholders of the Company.
Pursuant to the SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015, the brief profile of the Mr. Rishav Mehta is enclosed herewith.
You are requested to kindly take the same on record.
Thanking you,
Encl: As above
BRIEF PROFILE OF MR. RISHAV MEHTA EXECUTIVE DIRECTOR
Name of the Director
Mr. Rishav Mehta (DIN: 00015407)
Date of re-appointment
The Current term of Mr. Rishav Mehta Executive
Director is going to expire on 22nd March 2023.
Mr. Rishav Mehta has been proposed to be
reappointed as Executive Director of the
Company for a period of next five year w.e.f 23rd
March 2023 subject to the approval of
shareholder in Ensuing Annual General meeting.
Type
Executive Director
Age
31 Years
Date of Appointment
Re-appointment with effect from 23rd March,
2023.
Qualification
Graduate
Expertise
Mr. Rishav Mehta, Executive Director, Ind-Swift
Laboratories Ltd. is having over eight years of
experience in pharmaceutical industry, project
planning & control. He is playing active role in
production management and development of
new generic products.
Directorships held in other Companies
IND SWIFT LIMITED
DASHMESH MEDICARE PRIVATE LIMITED
ESSIX BIOSCIENCES LIMITED
VIBRANT AGRO INDUSTRIES LIMITED
No. of Equity Shares held in the Company
4,54,545 equity shares of Rs. 10 each
Information as required pursuant to BSE Circular
Mr. Rishav Mehta is not debarred from holding
with ref. no. LIST/COMP/14/2018-19
the office of director by virtue of any SEBI order or
any other such authority.
Relationship Between Directors/ KMP inter-se
Mr. Rishav Mehta is not related to any other
Director of the Company
Attachments
Original Link
Original Document
Permalink
Disclaimer
Ind-Swift Laboratories Ltd. published this content on 10 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 August 2022 17:30:05 UTC.
Ind-Swift Laboratories Limited is an India-based company. The Company is engaged in the business of manufacturing intermediates and formulations. The Companyâs products or services include Advanced Intermediates. It is API partner for many organizations both in generic and innovative domains. The Company offers reference standards and impurities for various active pharmaceutical ingredients (APIs) under British Pharmacopoeia (BP), European Pharmacopoeia (EP), British Pharmacopoeia (BP) and others. Its impurity portfolio is stocked with a range of standards for supply. The Company offers reference standards and impurities for over 25 APIs. All impurities are shipped with full documentation, including a Certificate of Analysis and MSDS. The research center, spread over the area of 40,000 square feet, is engaged in developing process technology for APIs in different therapeutic categories.